|1.||Jean-Claude, Bertrand J: 3 articles (08/2005 - 01/2003)|
|2.||McNamee, James P: 2 articles (08/2005 - 01/2003)|
|3.||Brahimi, Fouad: 2 articles (08/2005 - 03/2004)|
|4.||Matheson, Stephanie L: 2 articles (03/2004 - 01/2003)|
|5.||Rachid, Zakaria: 1 article (08/2005)|
|6.||Alaoui-Jamali, Moulay A: 1 article (08/2005)|
|7.||Tari, Ana M: 1 article (08/2005)|
|8.||Matheson, S L: 1 article (03/2001)|
|9.||Jean-Claude, B J: 1 article (03/2001)|
|10.||McNamee, J: 1 article (03/2001)|
|1.||Breast Neoplasms (Breast Cancer)
03/15/2004 - "The results showed that SMA41 degraded to SMA52 in the carcinoma of the vulva cell line A431 with a half-life of 11min. "
01/01/2003 - "Previous studies have demonstrated enhanced potency associated with the binary [DNA/epidermal growth factor receptor (EGFR)] targeting properties of SMA41 (a chimeric 3-(alkyl)-1,2,3-triazene linked to a 4-anilinoquinazoline backbone) in the A431 (epidermal carcinoma of the vulva) cell line. "
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/01/2001 - "The mixed epidermal growth factor receptor (EGFR)-DNA targeting properties of SMA41, a 6-(3-methyl-1,2,3-triazen-1-yl)-4-anilinoquinazoline designed to release N(4)-m-tolyl-quinazoline-4,6-diamine henceforth referred to as SMA52 [an inhibitor of EGFR tyrosine kinase (TK)] and methyldiazonium (a DNA methylating species) were studied in the O(6)-methylguanine-DNA methyltransferase (MGMT)-proficient and high EGFR-expressing epidermoid carcinoma of the vulva cell line A431. "
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|2.||DNA (Deoxyribonucleic Acid)
|3.||A-Form DNA (A-DNA)
|5.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)